Article Text

PDF
Response to: ‘Comment on “Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers’ effectiveness in axial spondyloarthritis: results of a prospective, multicentre study” by Moltó et al: still a long way to go in the assessment of patients with spondyloarthritis and concomitant fibromyalgia?’ by Altobelli et al
  1. Anna Moltó1,2,
  2. Maxime Dougados1,2
  1. 1Rheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France
  2. 2Clinical Epidemiology and Biostatistics, INSERM (U1153), PRES Sorbonne Paris-Cité, Paris, France
  1. Correspondence to Dr Anna Moltó, Rheumatology B Department, Cochin Hospital, Paris 75014, France; anna.molto{at}cch.aphp.fr

Statistics from Altmetric.com

We would like to thank Altobelli et al1 for the interest they have expressed in our recently published article ‘Evaluation of the impact of concomitant fibromyalgia on tumor necrosis factor (TNF) alpha blockers’  effectiveness in axial spondyloarthritis (axSpA) : results of a prospective multicentre study’2 and the ARD editorial team to give us the opportunity to address their comments in this present letter.

First, we would like to emphasise that the purpose of this study was not to address the effectiveness of non-steroidal anti-inflammatory drugs (NSAIDs,) antidepressants or third-ladder analgesics, but to evaluate the effectiveness of TNF alpha blockers in an axSpA population and the potential impact of a concomitant fibromyalgia on such …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles